
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is considered the market leader in the next generation sequencing market and has a strong foothold in both the academic research and medical diagnostics market. The company's clinical segment, which makes up more than half of its revenue, has seen sustained growth in recent years, primarily driven by increased demand for oncology testing and screening applications. While competition in the market is strong, management has taken a proactive approach in addressing it by focusing on long-term strategies and building customer relationships rather than engaging in price wars. The company's focus on innovation, improved margins, and new product launches also bode well for its future growth potential. Overall, the sustainability of Illumina's business model, its strong financials, and progressive initiatives make it a favorable investment option in the life sciences tools industry.
Bears say
Illumina is facing several headwinds that could impact its financial performance in the near future. The company's reliance on the Chinese market has been hindered by their placement on the unreliable entity list, and there is no clear resolution in sight. Additionally, the recently announced partnership with SomaLogic is not expected to have a significant impact on revenue growth and could potentially dilute earnings. The company also faces competition from multiple players in the next-generation sequencing market, which could impact their market share and margins. As such, there are several risks to the company's outlook, including a decline in clinical growth, weak demand in the academic channel, and a continued decline in sales in China.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares